We are live on ! Find out more
VKTXW

Viking Therapeutics, Inc.
VKTXW

Delisted

VKTXW was delisted on the 8th of April, 2021.

Back to rankings

4 hedge funds and large institutions have $1.03M invested in Viking Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

70% less capital invested

Capital invested by funds: $3.39M → $1.03M (-$2.36M)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UBS Group
UBS Group
Switzerland
+$68.1K

Top Sellers

1
William Blair & Company
William Blair & Company
Illinois
-$517K
Name Holding Trade Value Shares
Change 		Change in
Stake
PWAM
1
Park West Asset Management
California
$582K – – –
William Blair & Company
2
William Blair & Company
Illinois
$375K -$517K -49,300 -44%
UBS Group
3
UBS Group
Switzerland
$57K +$68.1K +6,497 +229%
US Bancorp
4
US Bancorp
Minnesota
$18K – – –

VKTXW Hedge Fund Activity: Q4 2018 in Review

4 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics, Inc. (VKTXW) for Q4 2018, worth a combined $1.03M — down 70% from $3.39M a quarter earlier.

Fund positioning in VKTXW was balanced in Q4 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, adding an estimated $68.1K. The largest seller was William Blair & Company, cutting an estimated $517K.

  • 4 institutional investors held Viking Therapeutics, Inc. (VKTXW) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $1.03M of Viking Therapeutics, Inc. stock for Q4 2018, down 70% quarter-over-quarter.
  • 0 funds opened new Viking Therapeutics, Inc. positions in Q4 2018 and 0 closed out.
  • The largest Viking Therapeutics, Inc. buyer in Q4 2018 was UBS Group, an estimated $68.1K added.
  • The largest Viking Therapeutics, Inc. seller in Q4 2018 was William Blair & Company, an estimated $517K sold.

Based on aggregated 13F filings for Q4 2018.